Management of antibiotic-associated pseudomembranous colitis

Area of Science:

• Gastroenterology
• Infectious Diseases
• Pharmacology

Background:

• Antibiotic-associated pseudomembranous colitis (AAPMC) is an uncommon but serious adverse reaction to antibiotics and antineoplastic agents.
• It results from Clostridium difficile proliferation and cytotoxin release, leading to pseudomembranous lesions and symptoms like diarrhea and abdominal pain.
• Symptoms can manifest from four days into therapy up to 10 weeks after discontinuation.

Purpose of the Study:

• To review the diagnosis, etiology, epidemiology, and drug therapy of antibiotic-associated pseudomembranous colitis (AAPMC).
• To provide guidance on the management of AAPMC, including therapeutic options and their efficacy.

Main Methods:

• Review of existing literature on diagnosis, etiology, epidemiology, and drug therapy of AAPMC.
• Analysis of treatment strategies, including discontinuation of the causative agent, fluid/electrolyte replacement, and specific anticlostridial antibiotics.
• Evaluation of the effectiveness and cost-benefit of different therapeutic agents like vancomycin, metronidazole, and bacitracin.

Main Results:

• Mild AAPMC cases may resolve with supportive care and discontinuation of the offending agent.
• Severe cases require anticlostridial antibiotic therapy; oral vancomycin is recognized but expensive and unpalatable.
• Metronidazole and bacitracin show good results, are less expensive, and are recommended for initial therapy in moderate to severe AAPMC. Relapse rates for all therapies range from 20-39%.

Conclusions:

• Successful AAPMC management involves a complex interplay of intestinal flora, immune response, and antibiotic use.
• For moderate to severe AAPMC, initial treatment should involve metronidazole or bacitracin.
• Vancomycin should be reserved for refractory cases, relapses, or patients with allergies to other agents.